Study of PETMRI for Diagnosing and Predicting Outcomes in Cardiac Sarcoidosis

What this Trial Is About

Cardiac damage is a major cause of death in patients with sarcoidosis, second only to lung damage. Researchers are studying the use of combined PET Positron Emission Tomography and MRI Magnetic Resonance Imaging scans as a way to better diagnose and predict the progression of cardiac sarcoidosis. This approach aims to improve risk assessment, especially for sudden death, and to help guide therapies and device implantation. Participants with suspected cardiac sarcoidosis will undergo PETMRI scans using a new hybrid camera that conducts FDG positron emission tomography along with gadolinium-enhanced MRI. This diagnostic method may help distinguish between fibrotic scarring and active granulomatous lesions and assess how patients respond to treatment. The study is prospective and comparative, involving multiple centers. During the study, researchers will monitor participants for up to 24 months, tracking occurrences of severe heart-related events. They will assess diagnostic accuracy, compare imaging results before and after treatment at 3 and 12 months, and evaluate metabolic activity and tissue changes. The study involves consented adults with sarcoidosis who have signs or symptoms suggesting cardiac involvement. Regular follow-up includes imaging assessments and clinical monitoring to evaluate prognosis and therapeutic response.

Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis